These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26415374)

  • 41. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins.
    Bakshi NA; Gulbranson R; Garstka D; Bradwell AR; Keren DF
    Am J Clin Pathol; 2005 Aug; 124(2):214-8. PubMed ID: 16040291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of Serum Free Light Chain Ratio and Normalization Ratio after Treatment on Diagnosis and Prognosis of Patients with Newly Diagnosed Multiple Myeloma].
    Li ZQ; Tian WW; Guo YF; Ma LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1245-1250. PubMed ID: 32798406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
    Heaney JLJ; Campbell JP; Griffin AE; Birtwistle J; Shemar M; Child JA; Gregory WM; Cairns DA; Morgan G; Jackson G; Drayson MT
    Br J Haematol; 2017 Jul; 178(2):220-230. PubMed ID: 28573706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum immunoglobulin free light chain and heavy/light chain measurements in POEMS syndrome.
    Wang C; Su W; Zhang W; Di Q; Duan MH; Ji W; Cao XX; Zhou DB; Li J
    Ann Hematol; 2014 Jul; 93(7):1201-6. PubMed ID: 24482101
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L; Tian Z; Fang Q
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains.
    Pratt G; Mead GP; Godfrey KR; Hu Y; Evans ND; Chappell MJ; Lovell R; Bradwell AR
    Leuk Lymphoma; 2006 Jan; 47(1):21-8. PubMed ID: 16321823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
    Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
    J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
    Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
    Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
    Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK
    Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
    Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
    Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.
    Pratt G; Harding S; Holder R; Fegan C; Pepper C; Oscier D; Gardiner A; Bradwell AR; Mead G
    Br J Haematol; 2009 Jan; 144(2):217-22. PubMed ID: 19016722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
    Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
    Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Analysis of monoclonal protein in 72 cases of multiple myeloma].
    Yang JJ; Zhang GS; Chen XR
    Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):152-4. PubMed ID: 12536652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.
    Barley K; Tindle S; Bagiella E; Jagannath S; Chari A
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):541-5. PubMed ID: 26119495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
    Granger Vallée A; Chenine L; Leray-Moragues H; Patrier L; Cognot C; Cartron G; Cristol JP; Canaud B
    Nephrol Dial Transplant; 2011 Nov; 26(11):3627-33. PubMed ID: 21508098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Appraisal of immunoglobulin free light chain as a marker of response.
    Dispenzieri A; Zhang L; Katzmann JA; Snyder M; Blood E; Degoey R; Henderson K; Kyle RA; Oken MM; Bradwell AR; Greipp PR
    Blood; 2008 May; 111(10):4908-15. PubMed ID: 18364469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
    Aref S; Goda T; El-Sherbiny M
    Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.